ArticleNeurochemical research2025
Hesperidin Attenuates Chronic Stress-Induced Depression via 5-HT2A-Linked Modulation of Neurochemical, Oxidative, and Inflammatory Pathways: Experimental and In Silico Evidence.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging Molecular Targets and Recent Advancements for the Management of Depression.Molecular neurobiology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Depression is associated with monoaminergic dysregulation, oxidative stress, and neuroinflammation, with the 5-hydroxytryptamine 2 A (5-HT2A) receptor playing a key role. The present study investigated the antidepressant-like potential of hesperidin (HSP), a citrus-derived flavonoid, administered chronically (100 or 200 mg/kg, orally once daily for 21 days) in mice exposed to chronic unpredictable mild stress (CUMS). These effects were further explored through 5-HT2A-associated neurochemical and molecular mechanisms, highlighting its role in stress-related neuroprotection. Exposure to CUMS produced depressive-like behavior, accompanied by increased corticosterone, oxidative stress, inflammation, and depletion of 5-HT and dopamine. Treatment with HSP effectively reversed these alterations by restoring sucrose preference, reducing immobility time in the forced swim test, and normalizing locomotor activity in the open field test. At the neurochemical level, HSP treatment reinstated 5-HT and dopamine levels, reduced corticosterone, and attenuated oxidative (MDA, GSH, SOD, catalase) and inflammatory (NF-κB, IL-1β, IL-6, TNF-α) markers. Moreover, HSP improved neuronal architecture, underscoring its neuroprotective potential. Co-administration of the 5-HT2A receptor agonist, (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI, 5 mg/kg, subcutaneously, once daily during the 21-day protocol) abolished HSP's effects, implicating 5-HT2A antagonism in its mechanism. In silico studies confirmed strong and stable binding of HSP to 5-HT2A receptors (- 72.99 kcal/mol), with key interactions involving Trp151, Asp155, Ser159, and Phe340. Molecular dynamics simulations (100 ns) supported complex stability. These results suggest that HSP exerts antidepressant-like effects by modulating 5-HT2A receptors, restoring HPA axis balance, reducing oxidative stress and neuroinflammation, and normalizing monoaminergic function.
Indexed as
Identifiers
41021139What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.